Many groups have recently targeted the CSCs effectively through the use of combination therapy of antibodies and conventional chemotherapeutic drugs against the CSC surface markers CD133+142 and drug efflux transporters.143 Yu et al.144 in their study eliminated CD133+ osteosarcoma CSCs through salinomycin delivery via CD133 aptamer-conjugated PEGylated PLGA nanoparticles. This evidence concerns the gene PROM1 and osteosarcoma.